VALIRX PLC
("ValiRx" or "the Company")
PATENT UPDATE
London, UK., 25 October 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces an update on its patents for the clinical stage therapeutic compounds VAL201 and VAL401, which are currently in Phase I/II and Phase IIB clinical trials to treat prostate and lung cancer respectively.
The Directors of ValiRx believe these developments further endorse, strengthen and validate the technology and intellectual property lying behind the Group's portfolio of drug assets.
New Japanese Patent Grant for VAL201
ValiRx announces that it has received patent approval by the Japanese Patent Office for VAL201.
The grant of this latest patent to the Company means that ValiRx now has patent protection in Japan, Europe and Australia and USA, with further patents pending in significant markets across the rest of the world, alongside other granted and patents pending for its therapeutic technologies world-wide.
Notification of a third US Patent Grant Allowance for VAL401
ValiRx is also pleased to announce that ValiSeek Limited ("ValiSeek"), the joint venture between ValiRx and Tangent Reprofiling Limited ("Tangent"), has received notification that a third US patent has been allowed by the US Patent Office covering the use of VAL401 in the treatment of pancreatic adenocarcinoma.
ValiSeek was formed to progress VAL401 into Clinical trials for the treatment of lung cancer and other oncology indications.
The directors of ValiSeek are pleased to see this patent grant allowance further strengthening ValiSeek's portfolio at an important time in VAL401's development pathway.
Dr Satu Vainikka, CEO of ValiRx, commented: "The grants of these latest patents further extend the Company's global geographic patent coverage and with the VAL201 patent grant also building nicely on our recent early clinical trial success".
Dr Suzanne Dilly, CEO of ValiSeek Limited, commented: "I am delighted to have this specific use indication added to our patent coverage in the US and it represents a further endorsement of the technology and science lying behind VAL401.
This announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx Plc |
Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive |
Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. |
Tel: +44 (0) 7879 458 364 [email protected] |
Mark Treharne, Corporate Development Manager |
Tel: +44 (0) 7736 564 686 [email protected] |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7148 7900 |
Liam Murray / Jo Turner |
|
|
|
Northland Capital Partners Limited (Joint Broker) |
Tel: +44 (0) 203 861 6625 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |
|
|
|
Beaufort Securities Limited (Joint Broker) |
Tel: +44 (0) 207 382 8300 |
Jon Belliss |
|
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.
About SEEK
Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.
Additional information about SEEK is available on the Company's website located at www.seekacure.com.
ValiRx Plc
ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
